MedTrace Logo

Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer

NCT02514213 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2017-12-26

No results posted yet for this study

Summary

This is a phase I, open-label trial to evaluate the safety and immunogenicity of INO 5150 alone or in combination with INO-9012 when delivered intramuscularly (IM) followed by electroporation (EP) in men with biochemically relapsed prostate cancer.

Conditions

Interventions

BIOLOGICAL

2mg INO-5150 and electroporation device CELLECTRA®-5P

2mg INO-5150 delivered IM followed by electroporation using CELLECTRA®-5P

BIOLOGICAL

8.5mg INO-5150 and electroporation device CELLECTRA®-5P

8.5 mg INO-5150 delivered IM followed by electroporation using CELLECTRA®-5P

BIOLOGICAL

2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P

2mg INO-5150 plus 1 mg INO9012 delivered IM followed by electroporation using CELLECTRA®-5P

BIOLOGICAL

8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P

8.5mg INO-5150 plus 1 mg INO9012 delivered IM followed by electroporation using CELLECTRA®-5P

DEVICE

Electroporation using CELLECTRA®-5P

Electroporation device CELLECTRA®-5P

Sponsors & Collaborators

Principal Investigators

  • Ildi Csiki, MD, PH.D. · Inovio Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2017-12-12
Completion
2017-12-12

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02514213 on ClinicalTrials.gov